Articles related to ANTIBIOTICS

Uncover the potential link between the widely used antibiotic cefepime and neurotoxicity in patients, particularly those with renal impairment, and understand how timely monitoring and management of cefepime levels could prove to be a vital aspect of patient care.

Find out more about the concerning trend in the treatment of uncomplicated UTIs at emergency departments, and discover why so many patients may not be receiving the IDSA-recommended treatment.

The burgeoning use of procalcitonin testing in hospital medicine underscores its potential to guide antibiotic decisions, particularly during diagnostic uncertainty, while highlighting the need for effective clinician behavior change strategies and an understanding of the test’s limitations.

Dive into this CME program to grasp the latest C. difficile guidelines and implement treatment strategies effectively. This interactive CME program focuses on Clostridioides difficile, or C. difficile. As you know, this bacterium causes severe GI disturbances. Alarmingly, it impacts half a million Americans annually and burdens the healthcare system. Who is this for? Infectious disease physicians, gastroenterologists, hospitalists, intensivists, and all HCPs managing patients with C. difficile infection (CDI) will benefit greatly. Initially, the program offers a comprehensive review of CDI. It presents the epidemiology and pinpoints key risk factors. Moreover, it explains the underlying pathophysiology and outlines clinical features. Significantly, it emphasizes the disease’s burden and unveils diagnostic tools, including NAAT, GDH assay, and toxin tests. Following this, the program shifts to treatment strategies for CDI. It details procedures for various severity levels – mild, severe, fulminant, and recurrent. Concurrently, it underlines the common challenges in therapy decision-making. Importantly, it stresses the necessity of adhering to CDI guidelines and presents preventative measures. In the concluding section, participants receive practical patient cases. This allows the application of newfound knowledge directly. Afterward, it wraps up with a summary and a best practice recap. Upon completion, participants will grasp the burden […]

In the first update in more than five years, these new guidelines review dosing recommendations for 41 antimicrobials, as applicable for patients with a BMI greater than or equal to 30 kg/m.

The authors present the findings of a large retrospective cohort study that used national data from the SEER-Medicare-linked database to better understand the relationship between antibiotics and PDAC survival. They discovered that perichemotherapy antibiotics were associated with improved survival in patients treated with first-line gemcitabine but not fluorouracil, implying that perichemotherapy antibiotic treatment may have a role in patients with metastatic PDAC receiving gemcitabine. Prospective studies on the effect of perichemotherapy antibiotics with high pancreatic penetration and gram-negative coverage on survival in diverse populations of patients with metastatic PDAC treated with gemcitabine are recommended.